MXPA03011094A - Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello. - Google Patents
Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.Info
- Publication number
- MXPA03011094A MXPA03011094A MXPA03011094A MXPA03011094A MXPA03011094A MX PA03011094 A MXPA03011094 A MX PA03011094A MX PA03011094 A MXPA03011094 A MX PA03011094A MX PA03011094 A MXPA03011094 A MX PA03011094A MX PA03011094 A MXPA03011094 A MX PA03011094A
- Authority
- MX
- Mexico
- Prior art keywords
- cytotoxins
- prodrugs
- linkers
- useful therefor
- stabilizers useful
- Prior art date
Links
- 231100000599 cytotoxic agent Toxicity 0.000 title abstract 3
- 239000002619 cytotoxin Substances 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- 239000003381 stabilizer Substances 0.000 title 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 abstract 1
- 229960005501 duocarmycin Drugs 0.000 abstract 1
- 229930184221 duocarmycin Natural products 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 125000001151 peptidyl group Chemical group 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion proporciona analogos de duocarmicinas que son citotoxinas potentes; tambien se proporcionan ligadores de peptidilo y disulfuro que se desdoblan in vivo; los ligadores tienen uso en la formacion de profarmacos y conjugados de las citotoxinas de la invencion, asi como otras porciones de diagnostico y terapeuticas; la invencion proporciona profarmacos y conjugados de analogos de duocarmicina con extremos ligadores de la invencion.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29534201P | 2001-05-31 | 2001-05-31 | |
US29525901P | 2001-05-31 | 2001-05-31 | |
US29519601P | 2001-05-31 | 2001-05-31 | |
US30490801P | 2001-07-11 | 2001-07-11 | |
PCT/US2002/017210 WO2002096910A1 (en) | 2001-05-31 | 2002-05-31 | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03011094A true MXPA03011094A (es) | 2004-12-06 |
Family
ID=27501653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03011094A MXPA03011094A (es) | 2001-05-31 | 2002-05-31 | Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello. |
Country Status (11)
Country | Link |
---|---|
US (8) | US7129261B2 (es) |
EP (2) | EP1434778A4 (es) |
JP (2) | JP4961095B2 (es) |
KR (1) | KR20030033007A (es) |
CN (2) | CN101671335A (es) |
AU (1) | AU2002303929B9 (es) |
CA (1) | CA2448319C (es) |
IL (2) | IL154183A0 (es) |
MX (1) | MXPA03011094A (es) |
NZ (1) | NZ529788A (es) |
WO (1) | WO2002096910A1 (es) |
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7425541B2 (en) * | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
JP4862120B2 (ja) * | 2001-02-22 | 2012-01-25 | ユニヴァーシティ オブ ブラッドフォード | 腫瘍治療のためのプロドラッグとしてのベンズ−インドールおよびベンゾ−キノリン誘導体 |
ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
IL154183A0 (en) * | 2001-05-31 | 2003-07-31 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
US20070122406A1 (en) | 2005-07-08 | 2007-05-31 | Xencor, Inc. | Optimized proteins that target Ep-CAM |
WO2003105845A1 (en) * | 2002-06-14 | 2003-12-24 | Takeda Chemical Industries, Ltd. | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers |
US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
EP1386927B1 (en) * | 2002-08-02 | 2005-03-30 | Institut Curie | Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
EP1617936B1 (en) * | 2003-02-19 | 2009-11-18 | Natrix Separations Inc. | Composite materials comprising supported porous gels |
ZA200507752B (en) * | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
SG173223A1 (en) | 2003-04-22 | 2011-08-29 | Ipsen Pharma Sas | Peptide vectors |
AU2004248138B2 (en) | 2003-05-29 | 2009-09-03 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
JP5189765B2 (ja) * | 2003-08-01 | 2013-04-24 | バイオコン・リミテッド | 加水分解可能なプロドラッグのためのアリールカルバメートオリゴマーおよびこれを含むプロドラッグ |
US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
WO2005097304A1 (en) * | 2004-04-08 | 2005-10-20 | Mcmaster University | Membrane stacks |
US20050239864A1 (en) * | 2004-04-23 | 2005-10-27 | Yuqiang Wang | Novel tumor-selective chemotherapeutic agents |
US7517903B2 (en) * | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
JP4806401B2 (ja) * | 2004-06-07 | 2011-11-02 | ナトリックス セパレイションズ インコーポレーテッド | 支持型多孔質ゲルを含む安定な複合材料 |
EP1765409A2 (en) * | 2004-06-30 | 2007-03-28 | Novartis AG | Conjugates of antibody and duocarmycin derivatives as antitumor agents |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
DK2325207T3 (en) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc variants with altered binding to FcRn |
WO2006089230A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
RS52505B (en) | 2005-06-29 | 2013-04-30 | Threshold Pharmaceuticals Inc. | PHOSPHORAMIDATE ALKYLATER PRODUCTS |
CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
WO2007051081A1 (en) * | 2005-10-26 | 2007-05-03 | Medarex, Inc. | Methods and compounds for preparing cc-1065 analogs |
WO2007059404A2 (en) * | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
PL1960434T3 (pl) | 2005-12-08 | 2012-12-31 | Squibb & Sons Llc | Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1 |
RS52804B (en) | 2005-12-08 | 2013-10-31 | Medarex Inc. | HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE |
WO2007084672A2 (en) | 2006-01-17 | 2007-07-26 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
US9603941B2 (en) * | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
MX2008009956A (es) * | 2006-02-02 | 2008-12-12 | Syntarga Bv | Analogos de cc-1065 solubles en agua y sus conjugados. |
ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
KR20090088852A (ko) | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법 |
SG177168A1 (en) | 2006-12-01 | 2012-01-30 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
NZ578354A (en) * | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
EP2114157B1 (en) * | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
TWI412367B (zh) * | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
WO2008091701A2 (en) * | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
JP2010519310A (ja) * | 2007-02-21 | 2010-06-03 | メダレックス インコーポレイテッド | 単一のアミノ酸を有する化学リンカーおよびその複合体 |
JP5618549B2 (ja) * | 2007-03-15 | 2014-11-05 | ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド | Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤 |
CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途 |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
EP2195017B1 (en) | 2007-10-01 | 2014-10-22 | Bristol-Myers Squibb Company | Human antibodies that bind mesothelin, and uses thereof |
US20090118031A1 (en) * | 2007-11-01 | 2009-05-07 | Qualizza Gregory K | Shaft Structure with Configurable Bending Profile |
TW200930407A (en) * | 2007-11-30 | 2009-07-16 | Medarex Inc | Conjugates of anti-RG-1 antibodies |
US20110152252A1 (en) * | 2007-12-18 | 2011-06-23 | Institut Curie | Shiga toxin b-subunit/chemotherapeutics conjugates |
EP3825329A1 (en) | 2007-12-26 | 2021-05-26 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US8246538B2 (en) * | 2008-02-28 | 2012-08-21 | K2M, Inc. | Minimally invasive retractor with separable blades and methods of use |
CA2724788C (en) | 2008-05-20 | 2016-12-06 | Neurogesx, Inc. | Hepatoprotectant acetaminophen mutual prodrugs |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
WO2010027955A2 (en) | 2008-09-02 | 2010-03-11 | Natrix Separations Inc. | Chromatography membranes, devices containing them, and methods of use thereof |
PT2344478T (pt) | 2008-11-03 | 2017-11-28 | Syntarga Bv | Análogos de cc-1065 e seus conjugados |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
MX2011009220A (es) | 2009-03-05 | 2011-09-28 | Medarex Inc | Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1. |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
EP2421898B1 (en) | 2009-04-20 | 2016-03-16 | Oxford BioTherapeutics Ltd | Antibodies specific to cadherin-17 |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
WO2011047083A1 (en) | 2009-10-13 | 2011-04-21 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
US20120282177A1 (en) | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
AU2010317563B2 (en) * | 2009-11-13 | 2014-06-19 | Merck Millipore Ltd. | Hydrophobic interaction chromatography membranes, and methods of use thereof |
HUE028629T2 (en) | 2009-12-23 | 2016-12-28 | Synimmune Gmbh | Anti-FLT3 antibodies and ways of their use |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
WO2011103421A1 (en) * | 2010-02-18 | 2011-08-25 | Shuber Anthony P | Compositions and methods for treating cancer |
CA2796712C (en) * | 2010-04-21 | 2017-02-28 | Syntarga B.V. | Novel conjugates of cc-1065 analogs and bifunctional linkers |
CA3051311A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
NZ604007A (en) | 2010-05-27 | 2015-03-27 | Genmab As | Monoclonal antibodies against her2 epitope |
EP3281956A3 (en) | 2010-06-15 | 2018-04-18 | Genmab A/S | Human antibody drug conjugates against tissue factor |
WO2012016227A2 (en) | 2010-07-29 | 2012-02-02 | Xencor, Inc. | Antibodies with modified isoelectric points |
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
JP6162606B2 (ja) | 2011-01-14 | 2017-07-12 | レッドウッド バイオサイエンス, インコーポレイテッド | アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 |
JP6239979B2 (ja) * | 2011-03-04 | 2017-11-29 | ニューヨーク・ユニバーシティ | Rasの調節因子としての水素結合代替大環状分子 |
WO2012143523A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
ES2968249T3 (es) | 2011-05-17 | 2024-05-08 | Merck Millipore Ltd | Dispositivo con membranas tubulares en capas para cromatografía |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN106110332B (zh) | 2011-06-10 | 2018-11-30 | 梅尔莎纳医疗公司 | 蛋白质-聚合物-药物共轭物 |
RS55716B1 (sr) | 2011-06-28 | 2017-07-31 | Oxford Biotherapeutics Ltd | Terapeutski i dijagnostički cilj |
KR102058185B1 (ko) | 2011-06-28 | 2019-12-20 | 옥스포드 바이오테라퓨틱스 리미티드 | Adp-리보실 시클라제 2에 대한 항체 |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
US9963481B2 (en) | 2011-09-07 | 2018-05-08 | The Scripps Research Institute | Chiral oligomeric pentenoate amides as bio-oligomer mimetics |
EP2766392B1 (en) | 2011-10-10 | 2019-07-17 | Xencor, Inc. | A method for purifying antibodies |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
EP2592103A1 (en) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Polymer aldehyde derivatives |
TW201336851A (zh) | 2012-02-13 | 2013-09-16 | 必治妥美雅史谷比公司 | 烯二炔化合物,其共軛物及彼等之用途與方法 |
CN107011358B (zh) * | 2012-04-05 | 2020-05-05 | 内尔维阿诺医学科学有限公司 | 新的烷化剂 |
WO2013160340A1 (en) * | 2012-04-25 | 2013-10-31 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
CN104540518A (zh) | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
GB201213652D0 (en) | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
WO2014027959A1 (en) | 2012-08-14 | 2014-02-20 | Nanyang Technological University | Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
US20140161790A1 (en) | 2012-11-19 | 2014-06-12 | Xencor, Inc. | Engineered immunoglobulins with extended in vivo half-life |
EP2922818B1 (en) | 2012-11-24 | 2018-09-05 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
KR20220156667A (ko) | 2013-01-10 | 2022-11-25 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
CN103933575B (zh) | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
MX356698B (es) | 2013-02-14 | 2018-06-11 | Bristol Myers Squibb Co | Compuestos de tubulisina, metodos para obtenerlos y uso. |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
WO2014145907A1 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Targeting t cells with heterodimeric proteins |
ES2885696T3 (es) | 2013-03-15 | 2021-12-15 | Xencor Inc | Proteínas heterodiméricas |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
ES2738657T3 (es) * | 2013-09-25 | 2020-01-24 | Nerviano Medical Sciences Srl | Derivados de tieno[2,3-e]indol como nuevos antitumorales |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
CN105979970B (zh) | 2013-10-11 | 2019-09-10 | 梅尔莎纳医疗公司 | 蛋白质-聚合物-药物共轭物 |
CN105813655B (zh) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
US10081682B2 (en) | 2013-10-11 | 2018-09-25 | Oxford Bio Therapeutics Ltd. | Conjugated antibodies against LY75 for the treatment of cancer |
WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
MX368396B (es) | 2014-01-10 | 2019-10-01 | Synthon Biopharmaceuticals Bv | Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada. |
PL3092010T3 (pl) | 2014-01-10 | 2019-01-31 | Synthon Biopharmaceuticals B.V. | Sposób oczyszczania połączonych cysteiną koniugatów przeciwciało-lek |
JP6224268B2 (ja) * | 2014-01-10 | 2017-11-01 | シントン・バイオファーマシューティカルズ・ビー.ブイ.Synthon Biopharmaceuticals B.V. | 子宮内膜癌の治療において使用するためのデュオカルマイシンadc |
ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
EP3647322B1 (en) | 2014-03-20 | 2021-10-20 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd38及びcd3に結合する二重特異性抗体 |
DK3151921T3 (da) | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf |
KR102586656B1 (ko) | 2014-07-11 | 2023-10-11 | 젠맵 에이/에스 | Axl에 결합하는 항체 |
WO2016014984A1 (en) | 2014-07-24 | 2016-01-28 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
PT3221346T (pt) | 2014-11-21 | 2020-10-23 | Bristol Myers Squibb Co | Anticorpos compreendendo regiões constantes de cadeia pesada modificadas |
MX2017006624A (es) | 2014-11-21 | 2017-08-21 | Bristol Myers Squibb Co | Anticuerpos contra cd73 y sus usos. |
CN107207379B (zh) | 2014-11-25 | 2021-08-10 | 百时美施贵宝公司 | 用于生物制品的18f-放射性标记的方法和组合物 |
AU2015353573B2 (en) | 2014-11-25 | 2020-09-03 | Bristol-Myers Squibb Company | Novel PD-L1 binding polypeptides for imaging |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
MA41019A (fr) | 2014-11-26 | 2021-05-05 | Xencor Inc | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |
EP3945096A1 (en) | 2014-12-19 | 2022-02-02 | Regenesance B.V. | Antibodies that bind human c6 and uses thereof |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
CA2973355A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
CN113876962A (zh) | 2015-04-07 | 2022-01-04 | 纪念斯隆-凯特琳癌症中心 | 纳米粒子免疫偶联物 |
CN106279352B (zh) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
EP3319993B1 (en) | 2015-07-10 | 2020-01-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
ES2809125T3 (es) | 2015-09-23 | 2021-03-03 | Bristol Myers Squibb Co | Moléculas de armazón a base de fibronectina de unión a glipicano-3 |
US10233212B2 (en) | 2015-11-03 | 2019-03-19 | Industrial Technology Research Institute | Compounds, linker-drugs and ligand-drug conjugates |
AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
CN109476740A (zh) | 2016-03-04 | 2019-03-15 | 百时美施贵宝公司 | 利用抗cd73抗体的联合治疗 |
WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
CN109562195A (zh) | 2016-06-01 | 2019-04-02 | 百时美施贵宝公司 | 用pd-l1结合多肽进行pet成像 |
US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
DK3468997T3 (da) | 2016-06-08 | 2023-10-02 | Xencor Inc | Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B |
RU2022104399A (ru) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
CN117683135A (zh) | 2016-07-14 | 2024-03-12 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
EP3500574B1 (en) | 2016-08-19 | 2021-11-24 | Bristol-Myers Squibb Company | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR102649972B1 (ko) | 2016-10-14 | 2024-03-22 | 젠코어 인코포레이티드 | IL15/IL15Rα 이종이량체 Fc-융합 단백질 |
US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
SG11201903693QA (en) | 2016-11-01 | 2019-05-30 | Genmab Bv | Polypeptide variants and uses thereof |
CN110099682B (zh) | 2016-11-14 | 2023-03-31 | 杭州多禧生物科技有限公司 | 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
WO2018151821A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
CN110621337B (zh) | 2017-05-10 | 2021-11-09 | 浙江时迈药业有限公司 | 抗lag3人单克隆抗体及其用途 |
KR20220167342A (ko) | 2017-05-25 | 2022-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
CA3067603A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
WO2019018892A1 (en) | 2017-07-26 | 2019-01-31 | The University Of Queensland | COMPOUNDS CONTAINING DISULFIDE BOND AND USES THEREOF |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
CA3084092A1 (en) | 2017-12-06 | 2019-06-13 | Ontario Institute For Cancer Research (Oicr) | Acyl hydrazone linkers, methods and uses thereof |
CA3086199A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
EP3728273A4 (en) | 2017-12-22 | 2021-12-29 | Ontario Institute for Cancer Research (OICR) | Heterocyclic acyl hydrazone linkers, methods and uses thereof |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
US20210107988A1 (en) | 2018-01-24 | 2021-04-15 | Genmab B.V. | Polypeptide variants and uses thereof |
WO2019183551A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
PE20201343A1 (es) | 2018-04-02 | 2020-11-25 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1 y usos de los mismos |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
WO2020003210A1 (en) | 2018-06-29 | 2020-01-02 | Kangwon National University University-Industry Cooperation Foundation | Anti-l1cam antibodies and uses thereof |
WO2020010079A2 (en) | 2018-07-02 | 2020-01-09 | Amgen Inc. | Anti-steap1 antigen-binding protein |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
TW202035445A (zh) | 2018-10-10 | 2020-10-01 | 美商帝洛斯療法股份有限公司 | 抗lap抗體變異體及其用途 |
EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
WO2020117627A1 (en) | 2018-12-03 | 2020-06-11 | Bristol-Myers Squibb Company | Anti-ido antibody and uses thereof |
CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
BR112021014106A2 (pt) | 2019-01-22 | 2021-10-13 | Bristol-Myers Squibb Company | Anticorpos contra subunidade alfa de il-7r e usos dos mesmos |
MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
US20220372139A1 (en) | 2019-07-15 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
US20220332817A1 (en) | 2019-07-15 | 2022-10-20 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
KR20220150274A (ko) | 2020-01-13 | 2022-11-10 | 네오이뮨텍, 인코퍼레이티드 | Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법 |
EP4110816A1 (en) | 2020-02-27 | 2023-01-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibodies binding il4r and uses thereof |
EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
CN114685669A (zh) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | 结合trop2的抗体及其用途 |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型cdcp1に対する抗体およびその使用 |
CA3234995A1 (en) | 2021-10-14 | 2023-04-20 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof |
Family Cites Families (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6A (en) * | 1836-08-10 | Thomas blanghard | ||
US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4978757A (en) | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
US4912227A (en) | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
CA1238907A (en) | 1984-02-21 | 1988-07-05 | Robert C. Kelly | 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JPH0684377B1 (es) | 1986-04-17 | 1994-10-26 | Kyowa Hakko Kogyo Kk | |
JP2598819B2 (ja) | 1986-12-19 | 1997-04-09 | ジ・アップジョン・カンパニー | 新規なcc‐1065同族体 |
US5332837A (en) | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
JPS6428264A (en) * | 1987-07-21 | 1989-01-30 | Sumitomo Electric Industries | Production of superconducting material |
US5773435A (en) | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
US4994578A (en) | 1987-11-27 | 1991-02-19 | Meiji Seika Kaisha, Ltd. | Certain anti-tumor duocarmycin antibiotics from streptomyces |
US5147786A (en) | 1988-04-22 | 1992-09-15 | Monsanto Company | Immunoassay for the detection of α-haloacetamides |
JP2642165B2 (ja) | 1988-07-22 | 1997-08-20 | 協和醗酵工業株式会社 | 新規dc−89化合物およびその製造法 |
US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US4915278A (en) * | 1988-11-03 | 1990-04-10 | Smith Kenneth W | Portable container |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質dc113 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3907562A1 (de) | 1989-03-09 | 1990-09-13 | Bayer Ag | Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung |
US5075181A (en) * | 1989-05-05 | 1991-12-24 | Kennametal Inc. | High hardness/high compressive stress multilayer coated tool |
WO1990013641A1 (en) | 1989-05-10 | 1990-11-15 | Sloan-Kettering Institute For Cancer Research | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
CA2058632C (en) | 1989-06-05 | 2004-08-24 | Brian C. Froehler | Exonuclease-resistant oligonucleotides and methods for preparing the same |
US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Dc―88a誘導体 |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5495009A (en) * | 1989-10-24 | 1996-02-27 | Gilead Sciences, Inc. | Oligonucleotide analogs containing thioformacetal linkages |
DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
CA2071483C (en) | 1989-10-24 | 2001-04-17 | Mark Matteucci | Oligonucleotide analogs with novel linkages |
US5334528A (en) | 1989-10-30 | 1994-08-02 | The Regents Of The University Of California | Monoclonal antibodies to cyclodiene insecticides and method for detecting the same |
US5180819A (en) | 1989-12-22 | 1993-01-19 | The Trustees Of Columbia University In The City Of New York | Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991011535A1 (en) | 1990-01-30 | 1991-08-08 | Childrens Hospital Of Los Angeles | Inhibition of transcription by double-stranded oligonucleotides |
AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
CA2078118C (en) | 1990-04-25 | 1999-11-16 | Paul A. Aristoff | Cc-1065 analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
ES2110444T3 (es) | 1990-06-11 | 1998-02-16 | Nexstar Pharmaceuticals Inc | Ligandos de acidos nucleicos. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
EP0468400B1 (en) | 1990-07-26 | 1996-08-14 | Kyowa Hakko Kogyo Co., Ltd. | DC-89 derivatives as antitumoral agents |
GB9017024D0 (en) | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5596086A (en) | 1990-09-20 | 1997-01-21 | Gilead Sciences, Inc. | Modified internucleoside linkages having one nitrogen and two carbon atoms |
AU8547691A (en) | 1990-09-21 | 1992-04-15 | Fred Hutchinson Cancer Research Center | Protein sequence-specific oligonucleotide sequences |
JPH04154298A (ja) * | 1990-10-17 | 1992-05-27 | Pioneer Electron Corp | スピーカ装置 |
AU9094991A (en) | 1990-11-23 | 1992-06-25 | Gilead Sciences, Inc. | Triplex-forming oligomers containing modified bases |
WO1992010590A1 (en) | 1990-12-10 | 1992-06-25 | Gilead Sciences, Inc. | Inhibition of transcription by formation of triple helixes |
WO1992014843A1 (en) | 1991-02-21 | 1992-09-03 | Gilead Sciences, Inc. | Aptamer specific for biomolecules and method of making |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
JPH0597853A (ja) | 1991-10-07 | 1993-04-20 | Kyowa Hakko Kogyo Co Ltd | Dc−89誘導体の臭化水素酸塩 |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
GB9314960D0 (en) * | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
JP3514490B2 (ja) * | 1992-08-21 | 2004-03-31 | 杏林製薬株式会社 | トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法 |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5324483B1 (en) | 1992-10-08 | 1996-09-24 | Warner Lambert Co | Apparatus for multiple simultaneous synthesis |
DE4314091A1 (de) | 1993-04-29 | 1994-11-03 | Boehringer Mannheim Gmbh | Immunologisches Nachweisverfahren für Triazine |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5502037A (en) * | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
US5773011A (en) | 1993-09-27 | 1998-06-30 | Gerbu Biotechnik Gmbh | Method of preparing a synergistic immunological adjuvant formulation |
US5786377A (en) * | 1993-11-19 | 1998-07-28 | Universidad De Santiago De Compostela | Pyrrolo 3,2-E!indol derivatives, process for the preparation thereof and applications |
DE4410559A1 (de) * | 1994-03-26 | 1995-09-28 | Hoechst Ag | Orientierte Polyolefinfolie mit amorphem Polymer, Verfahren zu ihrer Herstellung und ihre Verwendung |
KR100350260B1 (ko) | 1994-04-22 | 2003-01-06 | 교와 핫꼬 고교 가부시끼가이샤 | 피롤로인돌유도체 |
JPH07309761A (ja) * | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
AU694546C (en) * | 1994-08-19 | 2001-09-06 | La Region Wallonne | Compounds, pharmaceutical composition and diagnostic device comprising same and their use |
WO1996010405A1 (fr) | 1994-09-30 | 1996-04-11 | Kyowa Hakko Kogyo Co., Ltd. | Agent antitumoral |
US5580089A (en) * | 1994-10-11 | 1996-12-03 | Kolka; David B. | Vehicle stabilization system and method |
WO1996016965A1 (fr) | 1994-11-29 | 1996-06-06 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acrylamide et leur procede de production |
US5846645A (en) * | 1995-03-03 | 1998-12-08 | Asahi Glass Company Ltd. | Fluorocarbon resin-coated product |
CA2220339C (en) | 1995-05-10 | 2009-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Toxin conjugates having a spacer comprising polyalkylene glycol and peptide |
US5686237A (en) | 1995-06-05 | 1997-11-11 | Al-Bayati; Mohammed A. S. | Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5646298A (en) * | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5545805A (en) * | 1995-06-07 | 1996-08-13 | Chesner Engineering, Pc | Enhanced stabilization of lead in solid residues using acid oxyanion and alkali-metal carbonate treatment |
US5769650A (en) * | 1995-06-19 | 1998-06-23 | Sumitomo Wiring Systems, Ltd. | Connector and cover therefor |
US6548530B1 (en) | 1995-10-03 | 2003-04-15 | The Scripps Research Institute | CBI analogs of CC-1065 and the duocarmycins |
CA2187969C (en) | 1995-10-17 | 2006-05-30 | Dale L. Boger | A template for solution phase synthesis of combinatorial libraries |
EP0871490B1 (en) | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
US5760072A (en) * | 1995-12-29 | 1998-06-02 | Pharmachemie B.V. | Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy |
US5685237A (en) * | 1996-01-16 | 1997-11-11 | David Lehrman | Extendable support foot for an ironing board |
US6143901A (en) | 1996-07-31 | 2000-11-07 | Genesoft, Inc. | Complex formation between dsDNA and pyrrole imidazole polyamides |
ES2244991T3 (es) | 1996-03-08 | 2005-12-16 | The Scripps Research Institute | Analogosmcbi de cc-1065 y las duocarmicinas. |
US5843937A (en) * | 1996-05-23 | 1998-12-01 | Panorama Research, Inc. | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents |
WO1997045411A1 (en) | 1996-05-31 | 1997-12-04 | The Scripps Research Institute | Analogs of cc-1065 and the duocarmycins |
WO1998009966A1 (fr) * | 1996-09-03 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives dc-89 |
US6130237A (en) * | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
JPH1087666A (ja) | 1996-09-18 | 1998-04-07 | Kyorin Pharmaceut Co Ltd | デュオカルマイシンsa及びその誘導体の製造中間体と製造方法 |
US6759509B1 (en) * | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
WO1998025900A1 (fr) | 1996-12-13 | 1998-06-18 | Shionogi & Co., Ltd. | Composes presentant une activite antitumorale |
AU738864B2 (en) | 1997-03-28 | 2001-09-27 | Scripps Research Institute, The | Sandramycin analogs |
US6132722A (en) * | 1997-05-07 | 2000-10-17 | Bristol-Myers Squibb Company | Recombinant antibody-enzyme fusion proteins |
JP2002503228A (ja) | 1997-05-22 | 2002-01-29 | ザ スクリップス リサーチ インスティテュート | デュオカルマイシンおよびcc−1065の類似体 |
US6316522B1 (en) | 1997-08-18 | 2001-11-13 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
US6262271B1 (en) | 1997-10-14 | 2001-07-17 | The Scripps Research Institute | ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins |
JP2001525382A (ja) | 1997-12-08 | 2001-12-11 | ザ スクリップス リサーチ インスティテュート | Cc−1065/デュオカルマイシン類似体の合成 |
JP3045706B1 (ja) | 1998-09-14 | 2000-05-29 | 科学技術振興事業団 | Dnaの特定塩基配列をアルキル化する化合物及びその合成法 |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
CA2354766A1 (en) | 1998-12-11 | 2000-06-15 | Coulter Pharmaceutical, Inc. | Prodrug compounds and process for preparation thereof |
CA2383358A1 (en) | 1999-08-31 | 2001-03-08 | Board Of Regents, The University Of Texas System | Methods and compositions of a novel serine protease inhibitor |
JP2003531821A (ja) | 1999-12-29 | 2003-10-28 | イムノージェン インコーポレーテッド | 改変型ドキソルビシンおよびダウノルビシンを含む細胞傷害性薬剤ならびにその治療上の使用 |
DE10008089A1 (de) | 2000-02-22 | 2001-10-31 | Biotechnolog Forschung Gmbh | Syntheseverfahren zur Herstellung von Tubulysinen |
EP1265921B1 (en) | 2000-03-16 | 2007-05-23 | Genesoft, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
WO2001083482A1 (en) | 2000-05-03 | 2001-11-08 | The Scripps Research Institute | Dna alkylating agent and activation thereof |
JP4061819B2 (ja) * | 2000-05-12 | 2008-03-19 | 独立行政法人科学技術振興機構 | インターストランドクロスリンク剤の合成方法 |
CA2411660C (en) | 2000-06-14 | 2011-03-01 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
AU2001275525B2 (en) | 2000-06-14 | 2007-04-26 | Medarex, Inc. | Tripeptide prodrug compounds |
CA2413149A1 (en) * | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Prodrug compounds with isoleucine |
WO2002015700A1 (en) | 2000-08-24 | 2002-02-28 | Coulter Pharmaceutical, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
IL154183A0 (en) * | 2001-05-31 | 2003-07-31 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
US6762179B2 (en) * | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
ES2364452T3 (es) * | 2001-06-11 | 2011-09-02 | Medarex, Inc. | Método para diseñar compuestos profármacos activados por cd10. |
JP2005502703A (ja) | 2001-09-07 | 2005-01-27 | ザ スクリプス リサーチ インスティテュート | Cc−1065およびデュオカルマイシンのcbi類似体 |
US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US20050123536A1 (en) | 2001-11-20 | 2005-06-09 | Che-Leung Law | Treatment of immunological disorders using anti-dc30 antibodies |
TW557623B (en) * | 2001-11-28 | 2003-10-11 | Ind Tech Res Inst | Integrated demodulator for single-phase input frequency modulation signal |
US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
AU2003253048A1 (en) | 2002-07-09 | 2004-01-23 | Morphochem Aktiengellschaft Fur Kombinatorische Chemie | Tubulysin conjugates |
EP1523493B1 (de) | 2002-07-09 | 2013-09-04 | Dömling, Alexander | Neue tubulysinanaloga |
AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
DE602004027888D1 (de) | 2003-02-20 | 2010-08-12 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihr |
WO2004101767A2 (en) * | 2003-05-13 | 2004-11-25 | The Scripps Research Institute | Cbi analogues of the duocarmycins and cc-1065 |
US7517903B2 (en) | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
US7180819B1 (en) | 2005-10-04 | 2007-02-20 | Lsi Logic Corporation | Converting dual port memory into 2 single port memories |
MX2008009956A (es) | 2006-02-02 | 2008-12-12 | Syntarga Bv | Analogos de cc-1065 solubles en agua y sus conjugados. |
-
2002
- 2002-05-31 IL IL15418302A patent/IL154183A0/xx unknown
- 2002-05-31 CA CA2448319A patent/CA2448319C/en not_active Expired - Fee Related
- 2002-05-31 JP JP2003500089A patent/JP4961095B2/ja not_active Expired - Lifetime
- 2002-05-31 WO PCT/US2002/017210 patent/WO2002096910A1/en active Application Filing
- 2002-05-31 KR KR10-2003-7001398A patent/KR20030033007A/ko active Search and Examination
- 2002-05-31 US US10/160,972 patent/US7129261B2/en not_active Expired - Lifetime
- 2002-05-31 NZ NZ529788A patent/NZ529788A/en not_active IP Right Cessation
- 2002-05-31 EP EP02731994A patent/EP1434778A4/en not_active Withdrawn
- 2002-05-31 CN CN200910173556A patent/CN101671335A/zh active Pending
- 2002-05-31 US US10/161,233 patent/US6989452B2/en not_active Expired - Lifetime
- 2002-05-31 MX MXPA03011094A patent/MXPA03011094A/es active IP Right Grant
- 2002-05-31 EP EP10178144A patent/EP2266986A1/en not_active Withdrawn
- 2002-05-31 US US10/161,234 patent/US7087600B2/en not_active Ceased
- 2002-05-31 CN CN02802159A patent/CN1463270A/zh active Pending
- 2002-05-31 AU AU2002303929A patent/AU2002303929B9/en not_active Ceased
-
2003
- 2003-01-29 IL IL154183A patent/IL154183A/en not_active IP Right Cessation
-
2005
- 2005-06-21 US US11/133,970 patent/US7498302B2/en not_active Expired - Lifetime
- 2005-09-12 US US11/224,580 patent/US7507420B2/en not_active Expired - Lifetime
-
2008
- 2008-05-23 US US12/126,731 patent/USRE41252E1/en not_active Expired - Lifetime
-
2009
- 2009-03-02 US US12/396,266 patent/US8034959B2/en not_active Expired - Fee Related
- 2009-03-04 US US12/397,834 patent/US7977465B2/en not_active Expired - Fee Related
- 2009-04-07 JP JP2009092549A patent/JP2009155342A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03011094A (es) | Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello. | |
WO2005112919A3 (en) | Self-immolative linkers and drug conjugates | |
SG147286A1 (en) | Manufacture of polyglumate-therapeutic agent conjugates | |
IL163573A0 (en) | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | |
MX2008002597A (es) | Proceso para preparar conjugados de anticuerpo y maytansinoide. | |
EP1507556A4 (en) | CALICHEAMICINE DERIVATIVE VECTOR-TYPE CONJUGATES | |
HN2000000051A (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
UA103758C2 (ru) | Конъюгаты олигомеров инсулина, их композиции и применение | |
HUS1300002I1 (hu) | Aurisztatin konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére | |
TW200600518A (en) | Conjugates of hydroxyalkyl starch and a protein | |
BR122018071968B8 (pt) | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga | |
WO2006020719A3 (en) | Aminoacid conjugates of beta - lapachone for tumor targeting | |
HK1120427A1 (en) | Anti-glypican-3 antibody | |
MXPA02010801A (es) | Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados. | |
CY1108274T1 (el) | Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων | |
HK1056573A1 (en) | Photochemical internalization for delivery of molecules into the cytosol | |
MXPA04001982A (es) | Factor ix modificado. | |
TW200635576A (en) | Releasable polymeric conjugates based on aliphatic biodegradable linkers | |
WO2007030577A3 (en) | Prodrugs of t3 and t4 with enhanced bioavailability | |
AU2002215904A1 (en) | Compounds with a branched linker | |
UA82983C2 (ru) | Полимерные коньюгаты найбластина и способы их использования | |
ATE280588T1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
WO2005002516A3 (en) | Leukocyte internalized peptide-drug conjugates | |
WO2005058421A3 (en) | Use of a compound having two gold (i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (i) atoms for the treatment of cancer | |
TW200616658A (en) | Endogenously-formed conjugate of albumin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |